Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
about
CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomyFluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema.Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literatureIdentification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.Fluocinolone acetonide for the treatment of diabetic macular edema.Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema.Reply to 'Comments on Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'.Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
P2860
Q30491050-616C04F6-3A9D-4F57-85B8-5B5998B9325CQ33705718-3D0E355D-E95D-4467-B095-C7757A20D7CAQ36304980-1500A267-FFAE-40AD-9904-0DAB0AA63A02Q36341458-8D85C644-39BC-4D06-9F25-61D106AD1743Q36407311-133E2776-E9D4-4B60-925C-21D42E693404Q38648612-DD0B1545-51BD-4AD0-A67C-17451ECD6BDBQ38665017-674907F1-A814-4347-86A2-7454D69336D1Q41250047-A9C16A4D-B440-4BC3-A7A1-AC227BFC11C6Q42425676-6F3E03EB-0540-46E0-B5C7-E747D748269DQ48021083-6F16B742-70A7-4230-94E2-8D5E8C9D8D36Q48021098-ABC88383-E66E-41B7-9F05-028DB048BF6AQ48021114-20E6F561-7776-4139-9C33-240957003B39
P2860
Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Use of flucinolone acetonide f ...... outcomes in real world setting
@ast
Use of flucinolone acetonide f ...... outcomes in real world setting
@en
type
label
Use of flucinolone acetonide f ...... outcomes in real world setting
@ast
Use of flucinolone acetonide f ...... outcomes in real world setting
@en
prefLabel
Use of flucinolone acetonide f ...... outcomes in real world setting
@ast
Use of flucinolone acetonide f ...... outcomes in real world setting
@en
P2093
P2860
P1433
P1476
Use of flucinolone acetonide f ...... outcomes in real world setting
@en
P2093
Ajay Bhatnagar
Andrej Kidess
Fahad Quhill
Ibrahim Elaraoud
Marie Tsaloumas
Walter Andreatta
P2860
P2888
P356
10.1186/S12886-015-0178-9
P577
2016-01-05T00:00:00Z
P5875
P6179
1016910101